

Cloning and further sequence analysis of the spike gene of attenuated porcine epidemic diarrhea virus DR13

Seong-Jun Park · Dae-Sub Song · Gun-Woo Ha ·
Bong-Kyun Park

Received: 17 April 2006 / Accepted: 22 August 2006 / Published online: 27 October 2006
© Springer Science+Business Media, LLC 2006

Abstract The spike (S) gene of the attenuated porcine epidemic diarrhea virus (PEDV) DR13 was cloned and sequenced to further explore the functions of wild type PEDV and attenuated PEDV. Sequencing revealed a single large ORF of 4,149 nucleotides encoding a protein of 1,382 amino acids with predicted M_r of 151 kDa. The coding region of the S gene of attenuated PEDV DR13 had 20 nucleotide changes that appeared to be significant determinants of function in that they produced changes in its predicted amino acid sequence. Notably, attenuated PEDV DR13 has previously been found to exhibit reduced pathogenicity in pigs. The regions containing these 20 nucleotide changes may therefore be crucial for PEDV pathogenicity. The attenuated PEDV DR13 S protein contains 28 Asn-Xaa-Ser/Thr sequons, 21 asparagines that are predicted to be N-glycosylated and a stretch of highly hydrophobic residues at positions 1,327–1,347, which is predicted to form an α -helix and to function as a membrane

anchor. One (from N to K at 378) of the changes in the deduced amino acid sequence destroyed N-linked glycosylation sites, while another change (from N to S at 114) created a new one at a different location. These alterations in N-linked glycosylation sites reflected 3 nucleotide changes, which were related to the above-mentioned nucleotide changes and are suggested to influence the pathogenicity of attenuated PEDV DR13. Attenuated PEDV DR13 has 96.5, 96.4, 96.1, 93.9, 93.5 and 96.6% DNA sequence identities with CV777, Br1/87, JS-2004-2, Spk1, Chinju99 and parent DR13, respectively. Likewise, it shares 95.7, 95.4, 95.6, 92.0, 91.6 and 95.7% identity with those genes at the deduced amino acid sequence level. Phylogenetic analysis suggested that attenuated PEDV DR13 is closely related to CV777, Br1/87, JS-2004-2 and parent DR13, rather than to Spk1 and Chinju99 and is especially close to the Chinese PEDV strain JS-2004-2.

Keywords Porcine epidemic diarrhea virus · S gene · Cloning · Pathogenicity · Phylogenetic analysis

Nucleotide sequence data reported is available in the GenBank database under the Accession Nos. DQ462404 and DQ862099.

S.-J. Park (✉) · B.-K. Park
Department of Veterinary Medicine Virology Lab, College of Veterinary Medicine and BK21 Program for Veterinary Science, Seoul National University, Gwanak-gu, Seoul 151-742, Korea
e-mail: parkx026@snu.ac.kr

D.-S. Song
Research Unit, Green Cross Veterinary Products, Yong-In 449-903, Korea

G.-W. Ha
Animal genetics, Suwon, Korea

Porcine epidemic diarrhea virus (PEDV), a member of the family *Coronaviridae*, is an enveloped, single-stranded RNA virus [1–3]. It causes a devastating enteric disease with acute diarrhea, dehydration and significant mortality in swine, thereby incurring heavy economic losses in Asia [4, 5]. Although serologically unrelated, PEDV and transmissible gastroenteritis virus (TGEV), cause digestive tract infections which are extremely difficult to differentiate clinically [6–8]. Both viruses belong to the family *Coronaviridae*.

The spike (S) gene of TGEV is an important site of virus neutralization [9–11]. In addition, it is known that

determinants that confer TGEV enteropathogenicity are associated with the S gene [12]. Similarly for mouse hepatitis virus (MHV), it has been reported that mutations or deletions in its S gene markedly affect its neurovirulence [13, 14].

Genetic changes have been reported in the S gene of cell culture-adapted PEDV [15, 16]. These changes appear to have resulted from passage of the virus through cell cultures. Similarly, *in vivo*, the pathogenicity of PEDV in piglets was reduced through serial passage in Vero cell cultures [16]. Moreover, the S gene has been suggested as an important determinant for PEDV biological properties.

Reading in the 5′–3′ direction, the PEDV genome contains genes for pol1 (P1) protein, spike (S) protein, an open reading frame (ORF3), envelope (E) protein, membrane (M) protein and nucleocapsid (N) protein [10, 17–21]. Among the proteins encoded by these genes, S protein, a glycoprotein peplomer (surface antigen) on the viral surface, plays an important role in binding to specific host cell receptor glycoproteins with subsequent penetration into the cells occurring via membrane fusion. The S protein also stimulates induction of neutralizing antibodies in the host [10].

The PEDV DR13 strain, which is highly adapted to cell culture, exhibited reduced pathogenicity and induced immunogenicity in pigs [16]. These changes may have resulted from adaptation and attenuation through serial passage in Vero cell cultures [16, 22]. Although unexpected, this attenuation of PEDV DR13 through serial passage may be of strategic interest.

In this study, we constructed DNA clones of the PEDV DR13 S gene. In order to elucidate the genetic basis of the markedly different wild type and attenuated PEDV phenotypes, the nucleotide and deduced amino acid sequences of the S gene were determined and were further analyzed and aligned with those of reference PEDVs [16]. Furthermore, phylogenetic trees were constructed and analyzed on the basis of the S gene nucleotide and deduced amino acid sequences. The similarities and differences between reference PEDVs and attenuated PEDV DR13 were elucidated. This analysis helped to elucidate the phylogenetic relationships between attenuated PEDV DR13 and other PEDV strains.

The continuous Vero cell line (ATCC, CCL-81) was regularly maintained in α -minimum essential medium (α -MEM) supplemented with 5% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 μ g/ml) and amphotericin B (0.25 μ g/ml).

Porcine epidemic diarrhea virus strain named DR13 was isolated from the intestinal tissues of piglets suspected with porcine epidemic diarrhea (PED),

which had been submitted to the Department of Veterinary Medicine Virology Laboratory, College of Veterinary Medicine, Seoul National University, Seoul, Korea. Intestinal samples were made into 10% (v/v) suspensions through homogenization with phosphate buffered saline (PBS; 0.1 M, pH 7.2). The suspensions were vortexed and clarified by centrifugation for 10 min at 4,800 \times g. Supernatants passed through a 0.2 μ m syringe filter (Acrodisk, Gelman) were used for virus isolation in Vero cells. Prior to inoculation, the growth media of confluent cells grown in 25-cm² flasks (Falcon, USA) were removed and the cells were washed three times with PBS (pH 7.4). Cells were inoculated with 1 ml per flask of the supernatants. After adsorption at 37°C for 1 h, the cells were incubated in α -MEM supplemented with 0.02% yeast extract, 0.3% tryptose phosphate broth, and 2 μ g of trypsin as described previously [16]. Serial passages of the DR13 isolate of PEDV were continued in a 25-cm² flask by level 100 according to the method described above. PEDV was identified by RT-PCR [23].

Infected cell cultures were prepared for the extraction of viral RNA. Infected cells were harvested when the cells reached 70–80% cytopathic effect (CPE). RNA was extracted from infected cells using TRIzol LS (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions. For PEDV-infected cells, 250 μ l suspensions were lysed directly in 1.7 ml microtubes by adding 750 μ l TRIzol LS reagent. Then 200 μ l of chloroform was added to the mixture, and the suspension was centrifuged for 10 min at 12,000 \times g. The RNA-containing aqueous phase was precipitated with isopropanol of the same volume, maintained at –70°C for 2 h, and centrifuged for 10 min at 12,000 \times g. The RNA pellet was washed with 1 ml of 75% ethanol, centrifuged for 10 min at 12,000 \times g, and dried, following which it was resuspended in 30 μ l of diethylpyrocarbonate (DEPC)-treated deionized water.

Pairs of sense and antisense primers were designed and aligned based on the nucleotide sequence of the S gene of CV777 and Br1/87 [10, 15] from the GenBank database (National Center for Biotechnology Information, USA). These primers were used to generate cDNA for the S gene of attenuated PEDV DR13. The nucleotide sequences and relative position of the primers are shown in Table 1 and Fig. 1, respectively.

RT-PCR was performed using a Maxime RT-PCR PreMix Kit (iNtRON BIOTECHNOLOGY, Korea), according to the manufacturer's instructions.

Briefly, for RT-PCR, 2 μ l aliquots of extracted RNA and 2 μ l of each specific primer (10 pmol) were added into the Maxime RT-PCR PreMix tubes and brought to 20 μ l with autoclaved, filtered (0.2 μ m) distilled

Table 1 Primers used in cDNA synthesis of the PEDV S gene

Primer	Nucleotide sequence	Mers	%GC	Strand
SF1	5'-TCATCCATTAGTGATGTTGTGTTA-3'	24	33.3	+
SR1	5'-GCCCGCAGAGACAGTAATATTAACA-3'	24	41.7	-
SF2	5'-GTGTTCTCAGGTTGCTTTTGACCT-3'	24	45.8	+
SR2	5'-AAAGACTCAGCAAGCAATTGCTGG-3'	24	45.8	-
SF3	5'-GTACAGTGCGTCTCTCATAGGTGG-3'	24	54.2	+
SR3	5'-TCTAATTGGAACACTACATTGAGCTC-3'	24	37.5	-

water. RT-PCR was performed using a commercial amplification system (Perkin-Elmer, Applied Biosystems, Foster City, Calif) and employed a program of 1 cycle of 30 min at 45°C and 5 min at 94°C and 40 cycles of 1 min at 94°C, 1 min at 57°C and 2 min at 72°C, and a final extension at 72°C for 5 min. RT-PCR products were visualized by electrophoresis in a 1.5% agarose gel containing ethidium bromide. Bands of the correct size were excised and purified using a QIAquick Gel Extraction Kit (QIAGEN) according to the manufacturer's instructions.

Purified RT-PCR products corresponding to the S gene were cloned using a QIAGEN PCR Cloning^{plus} Kit (QIAGEN) according to the manufacturer's instructions with simple modifications.

For cloning of cDNA, 4 µl of purified RT-PCR product, 1 µl of pDrive Cloning Vector (50 ng/ul) and 5 µl of 2× ligation Master Mix were mixed gently and incubated for 4 h at 16°C. The ligation-reaction mixture was then subjected to the transformation protocol, which renders cells competent through heat-shock. For transformation, a number of tubes of QIAGEN EZ Competent Cells were thawed on ice and SOC medium was warmed to room temperature following which 5 µl

of ligation-reaction mixture was added per tube of cells, mixed gently for 3 s and incubated on ice for 30 min. The tubes were heated in a 42°C water bath for 90 s and incubated on ice immediately. Room temperature SOC medium (250 µl) was added to each tube and 100 µl of each transformation mixture was immediately plated onto LB agar plates containing ampicillin. The plates were incubated at room temperature until the transformation mixture had absorbed into the agar, following which they were inverted and then incubated at 37°C overnight. Colonies grown in LB agar plates were cultured in LB broth with shaking at 37°C overnight, and DNA was extracted using the Wizard[®] Plus Minipreps DNA Purification System (Promega). Restriction enzyme digestion, with enzymes such as *EcoRI*, followed by electrophoresis through 1.5% agarose gels was employed for identification of recombinant DNA clones.

All S gene recombinant DNA clones were sequenced by Genotech Co. Ltd. (Korea). All sequencing reactions were performed in duplicate and all sequences were confirmed by sequencing both strands.

Nucleotide and deduced amino acid sequences were analyzed with the CLUSTALX v1.83 program and




Fig. 1 Construction of cDNA clones for the full-length S gene of attenuated PEDV DR13 by RT-PCR using pairs of sense (SF) and antisense (SR) primers: diagrammatic representation of the S gene of viral RNA (long solid rectangle) and S gene ORF (long

open rectangle) show primer-binding sites (small open rectangles). Three DNA fragments amplified by RT-PCR and cloned into the pDrive Cloning Vector are denoted as recombinant DNA clones Sfrag I, Sfrag II and Sfrag III

MegAlign software (DNASTar Inc., Madison, WI, USA) for alignment and sequence analysis. S gene nucleotide and deduced amino acid sequences were compared with the PEDV CV777 (GenBank Accession No. AF353511), Br1/87 (EMBL Accession No. Z25483), JS-2004-2 (GenBank Accession No. AY653204), Spk1 (GenBank Accession No. AF500215), Chinju99 (GenBank Accession No. AY167585) and parent DR13 (GenBank Accession No. DQ862099) strains.

Nucleotide and deduced amino acid sequences were edited and aligned with the CLUSTALX v1.83 and Bioedit v7.0.5.2 programs. The resulting subsets were edited manually. A phylogenetic tree was then generated using an alignment of S gene nucleotide and deduced amino acid sequences with the above-mentioned reference PEDVs by applying the neighbor-joining method in the MEGA 3.1 program. To assess the relative support for each clade, bootstrap values were calculated from 1,000 replicate analyses and the cut-off point for bootstrap replication was 70%.

To synthesize ds-cDNA of the attenuated PEDV DR13 S gene, three overlapping DNA fragments were amplified by RT-PCR using a proper pair of sense (SF) and antisense (SR) primers. The DNAs, designated as Sfrag I (1,654 bp), Sfrag II (1,593 bp) and Sfrag III (1,422 bp) were each cloned into the pDrive Cloning Vector DNA (Fig. 1) and subjected to sequencing.

Alignment of nucleotide and deduced amino acid sequences is presented in Fig. 2. This revealed that the nucleotide sequence encoding the entire attenuated PEDV DR13 S gene is 4,159 bases in length and contains a single 4,149-base ORF starting with an initiator, ATG, at position 11 nt and ending with a terminator, TGA, at position 4,157 nt. The coding region of the gene has 142 (146) and 141 nucleotide mismatches compared to CV777 (Br1/87) and parent DR13, and 3 missing nucleotides compared to CV777, Br1/87 and DR13, respectively. It consists of 1,011 adenine (24.31%), 842 cytosine (20.25%), 879 guanine (21.13%) and 1,427 thymine (34.31%) nucleotides, and has a GC content of 41.38%.

The attenuated PEDV DR13 S gene encodes a protein of 1,382 amino acids with predicted M_r of 151 kDa. There are 28 Asn-Xaa-Ser/Thr sequons and 21 asparagine residues that are predicted to be N-glycosylated in the protein. The attenuated PEDV DR13 S protein has 59, 63 and 59 amino acid mismatches compared to CV777, Br1/87 and parent DR13, respectively, and 1 missing amino acids compared to CV777, Br1/87 and parent DR13. There is also a stretch of highly hydrophobic residues at positions 1,327–1,347 (>1.6 on the Kyte-Doolittle scale).

Maximum value was 3.978 at position 1,333 and minimum was –2.444 at position 914.

Nucleotide and deduced amino acid sequence homology results are described in Table 2. We found that the attenuated PEDV DR13 S gene shares 96.5, 96.4, 96.1, 93.9, 93.5 and 96.6% DNA sequence identities with CV777, Br1/87, JS-2004-2, Spk1, Chinju99 and parent DR13, respectively. Likewise, it shares 95.7, 95.4, 95.6, 92.0, 91.6 and 95.7% homologies with the deduced amino acid sequences of the same genes.

Phylogenetic trees were generated on the basis of nucleotide and deduced amino acid sequences (Fig. 3). The left hand phylogenetic tree (Fig. 3a) was generated based on nucleotide sequences and the right hand tree (Fig. 3b) was based on deduced amino acid sequences. While these phylogenetic trees did differ slightly, overall they showed high similarity. In brief, all seven PEDVs, which were used for comparison, including attenuated PEDV DR13, fell into two groups. One group comprised CV777, Br1/87, JS-2004-2, parent DR13 and attenuated DR13. The second group consisted of Spk1 and Chinju99. The group containing CV777, Br1/87, JS-2004-2, parent DR13 and attenuated DR13 had two subgroups. Attenuated PEDV DR13 formed one subgroup with JS-2004-2 and the others formed another subgroup.

The S gene of the attenuated PEDV DR13 strain was successfully cloned and sequenced as a series of three overlapping cDNA clones. The sequencing results showed a single large ORF of 4,149 nucleotides encoding a protein of 1,382 amino acids with a predicted M_r of 151 kDa. A single ORF of 4,149 nucleotides, with the potential to encode the coronavirus S protein, was identified [24]. The PEDV DR13 S gene had a sequence (GUAAAC) of 8 nucleotides upstream of the initiator ATG, as previously recognized in Br1/87 [10]. This sequence is a hexameric motif common to coronaviruses and is similar to the hexameric motifs XUA(A/G)AC found adjacent to other PEDV ORFs. These hexameric motifs have been proposed as a starting site for the transcription of the subgenomic mRNAs [24].

Previous studies showed that wild type and cell culture adapted PEDV exhibit remarkably different phenotypes in terms of pathogenicity in piglets [16, 25]. Moreover, those two PEDV types have 5 nucleotide differences within their S gene coding sequences, and all of those changes are meaningful in that they produce changes in the predicted amino acid sequence [15]. However, these regions may not be crucial for pathogenicity, because these 5 nucleotide changes were not found in the attenuated PEDV DR13 strain.

The coding region of the S gene of attenuated PEDV DR13 has nucleotide and amino acid differences compared to CV777, Br1/87 and parent




Fig. 2 Comparison of the (a) nucleotide and (b) deduced amino acid sequence of the S gene of attenuated PEDV DR13 with CV777 (GenBank Accession No. AF353511), Br1/87 (EMBL Accession No. Z25483) and parent DR13 (GenBank Accession No. DQ862099) strains. Asterisks represent (a) nucleotides and (b) amino acids that are identical to those in the attenuated PEDV DR13. Dashed lines represent missing (a) nucleotides and (b) amino acids compared to the PEDV CV777, Br1/87 and parent DR13 strains. Start codon ATG and stop codon TGA are underlined. Only the (a) 142 (146) and 141 nucleotides, and (b)

59 (63) and 59 amino acids of CV777 (Br1/87) and parent DR13 which mismatched those of attenuated PEDV DR13 are included. Three missing nucleotides and one missing amino acids compared to the PEDV CV777, Br1/87 and parent DR13 strains are included. Regions corresponding to the six primers used for cloning are underlined and labeled above the sequence as SF1-3 and SR1-3. Asn-Xaa-Ser/Thr sequons in the sequence are underlined and bold letters indicate asparagine residues that are predicted to be N-glycosylated

DR13 (attenuated)	1431	1450	1451	1470	1471	1490	1491	1510	1511	1530	1531	1540	
DR13 (parent)	CTTTTGACCT	TGATGATGGT	TTTACCCTA	TTTCTCTAG	AAACCTCTG	AGTCATGAAC	AGCCAATTC	TTTTGTACT	TTGCCATCAT	TCAATGACCA	TTCTTTGTT		
CV777	*****	**C*****	*****C*	*C*****	*****	*****C***	*****	*****	*****	*T*****T*	*****	*****	
Brl/87	*****	**C*****	*****C*	*C*****	*****	*****C***	*****	*****	*****	*T*****T*	*****	*****	
DR13 (attenuated)	1541	SR1	1560	1561	1580	1581	1600	1601	1620	1621	1640	1641	1650
DR13 (parent)	AATATTACTG	TCCTCTCGGC	TTTTGGTGGT	CATAGTGGT	CAAACCTCAT	TGCATCTGAC	ACTACTATCA	ATGGGGTTAG	TTCTTCTGT	GTTGACACTA	GACAATTAC		
CV777	*****	*****T*	*****	*T***A**	***T***G*	*****	*****	*****	*****	*****	*****	*****	*****
Brl/87	*****	*****T*	*****	*T***A**	***T***G*	*****	*****	*****	*****	*****	*****	*****	*****
DR13 (attenuated)	1651	1670	1671	1690	1691	1710	1711	1730	1731	1750	1751	1760	
DR13 (parent)	CATTACACTG	TTTTATAAGC	TTACAAACAG	TTATGGTTAT	GTGTCTAAGT	CACAGGATAG	TAATTGCCCT	TTCACCTTGC	AATCTGTAA	TGATTACCTG	TCTTTTAGCA		
CV777	*****	*****T*	*****	*****	*****	*****T*	*****	*****	*****	*****	*****	*****	
Brl/87	*****	*****T*	*****	*****	*****	*****T*	*****	*****	*****	*****	*****	*****	
DR13 (attenuated)	1761	1780	1781	1800	1801	1820	1821	1840	1841	1860	1861	1870	
DR13 (parent)	AATTTTGTGT	TCAACACAGC	CTTTGGCTG	GTGCTGTAC	CATAGATCTT	TTTGGTACC	CTGAGTTCGG	TAGTGGTGT	AAGTTTACGT	CCCTTATTT	TCATTCACA		
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****G***	*****	*****	*****	
Brl/87	*****	*****	*****	*****	*****	*****	*****	*****	*****G***	*****	*****	*****	
DR13 (attenuated)	1871	1890	1891	1910	1911	1930	1931	1950	1951	1970	1971	1980	
DR13 (parent)	AAGGGTGAGT	CGATTACTGG	CAGCCTAAA	CAACTTCAAG	GTGTCAACGA	CGTTCTTTT	ATGACTCTGG	ATGTGTGTAC	CAAGTACT	ATCTATGGCT	TTAAAGGTGA		
CV777	**A*****	T*****G**	*****G**	*****A**	*****A**	*****	*****	*****	*****	*****	*****	*****	
Brl/87	**A*****	T*****G**	*****G**	*****A**	*****A**	*****	*****	*****	*****	*****	*****	*****	
DR13 (attenuated)	1981	2000	2001	2020	2021	2040	2041	2060	2061	2080	2081	2090	
DR13 (parent)	GGGTATTATT	ACCTTACCAA	ATTCTAGCTT	TTTGGCAGGT	GTTTATTATA	CATCTGATTC	TGGACAGTGG	TTAGCCTTTA	AGAATGTCAC	TAGTGGTGGC	GTTTATTCTG		
CV777	*****	*****	*****A*	*****	*****	*****	*****	*****	*****	*****	*****	*****	
Brl/87	*****	*****	*****A*	*****	*****	*****	*****	*****	*****	*****	*****	*****	
DR13 (attenuated)	2091	2110	2111	2130	2131	2150	2151	2170	2171	2190	2191	2200	
DR13 (parent)	TTACGCCACT	TTCTTTTCA	GAGCAGGCTG	CATATGTGAT	TGATGATATA	GTGGGTGTTA	TTTCTAGTTT	GTCTAATCC	ACTTTTAAAC	ATACCAAGGA	GTTGCGCTGGT		
CV777	*C*****	*****	*****	*****A*	*****	*****	*****	*****	*****	*****T***	*****	*****	
Brl/87	*C*****	*****	*****	*****A*	*****	*****	*****	*****	*****	*****T***	*****	*****	
DR13 (attenuated)	2201	2220	2221	2240	2241	2260	2261	2280	2281	2300	2301	2310	
DR13 (parent)	TTCTTACC	ATTCTAAGGA	TGCTCCAAT	TGTACAGAGC	CTGTGTGGT	GTATAGTAAAC	ATAGGTGTCT	GTAATCTGG	CAGTATTGGC	TATGTCCAC	TTCAGGATGG		
CV777	*****	*****	C*****	*****	*****T***	*****	*****T*	*****	*****	*****T***	C***T***	*****	
Brl/87	*****	*****T*	C*****	*****	*****T***	*****	*****T*	*****	*****	*****T***	C***T***	*****	
DR13 (attenuated)	2311	2330	2331	2350	2351	2370	2371	2390	2391	2410	2411	2420	
DR13 (parent)	CCAAGTCAAG	ATTGCACCCA	TGTTACTGG	GAATATTAGT	ATTCCACCA	ACTTTAGTAT	GAGTATTAGA	ACAGAATATT	TACAGCTTTA	CAACACGCT	GTTAGTGTG		
CV777	*****	*****	C*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
Brl/87	*****	*****	C*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
DR13 (attenuated)	2421	2440	2441	2460	2461	2480	2481	2500	2501	2520	2521	2530	
DR13 (parent)	ATTGCGTTAC	ATATGTTTGT	AATGGTAACT	CTCGTTGTA	ACAATTACTC	ACCCAGTACA	CTGCAGCATG	TAAGAACATA	GAGTCAGCAT	TACAACCTAG	CGCTAGGCTT		
CV777	***T*C**	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
Brl/87	***T*C**	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	
DR13 (attenuated)	2531	2550	2551	2570	2571	2590	2591	2610	2611	2630	2631	2640	
DR13 (parent)	GAGTCTGTG	AAGTTAACTC	TAGCTTACT	ATTTCTGAAG	AGGCTCTACA	GTTAGCTACC	ATCAGTTCGT	TTAATGTTGA	TGGATATAAC	TTTACTAATG	TGCTGGGTGT		
CV777	*****	*****	*****C	*****	*****T***	*****	*****	*****	*****	*****	*****C	*****	
Brl/87	*****	*****	*****C	*****	*****T***	*****	*****	*****	*****	*****	*****C	*****	
DR13 (attenuated)	2641	2660	2661	2680	2681	2700	2701	2720	2721	2740	2741	2750	
DR13 (parent)	TTCCGTGAC	GACCCGTCAA	GTGGCAGGGT	GGTACAAAA	GGTCTTTTA	TTGAAGACCT	GCTTTTAAAT	AAAGTGTTA	CTAATGCCCT	TGTTACTGTT	GATGAAGACT		
CV777	*****	*T*****	*****	*****	A***G**	*****T*	*****	*****	*****	*****	*****	*****	
Brl/87	*****	*T*****	*****	*****	A***G**	*****T*	*****	*****	*****	*****	*****	*****	
DR13 (attenuated)	2751	2770	2771	2790	2791	2810	2811	2830	2831	2850	2851	2860	
DR13 (parent)	ATAAGCGCTG	TTCTAATGGT	CGCTCTGTGG	CAGATCTAGT	CTGTGCGCAG	TATTACTCTG	GTGTGATGGT	ACTACCTGGC	GTTGTTGACG	CTGAGAGCT	TCACATGTAT		
CV777	*****	*****	*****	*T*****	*****	*****	*****	*****	*****	*****	*****C	*****	
Brl/87	*****	*****	*****	*T*****	*****	*****	*****	*****	*****	*****	*****C	*****	
DR13 (attenuated)	2861	SR3	2880	2881	2900	2901	2920	2921	2940	2941	2960	2961	2970
DR13 (parent)	AGTGCCTCTC	TCATCGGTGG	TATGCGCCTA	GGAGTCTTA	CTAGTGCAGC	GGCATTGTCT	TTAGCCATG	CTGTCAAGC	GAGGCTCAAT	TATCTTGCCT	TACAGACGGA		
CV777	*****	***A***	*****	*****A+A*	*GC***	*****C*	*****T*	*****	*****A***	*****	*****	*****	*****
Brl/87	*****	***A***	*****	*****A+A*	*GC***	*****C*	*****T*	*****	*****A***	*****	*****	*****	*****

Fig. 2 continued

DR13 as described above. Out of all differences, 50 nucleotide and 20 amino acid changes of the attenuated PEDV DR13 appear to be meaningful because we reveal other changes found in wild type PEDV, including JS-2004-2, Spk1, Chinju99 and parent DR13. Notably, only 20 nucleotide changes, however, are thought to be significant for pathogenicity because

they lead to changes in the predicted amino acid sequence of attenuated PEDV DR13. In addition, attenuated PEDV DR13 exhibited reduced pathogenicity in pigs when subjected to a high number of serial passages in Vero cell cultures [16].

The attenuated PEDV DR13 S protein was found to contain 28 Asn-Xaa-Ser/Thr sequons, 21 asparagines

	2971	2990	2991	SR2	3010	3011	3030	3031	3050	3051	3070	3071	3080
DR13 (attenuated)	TGTTCTACAG	CGCAACCAGC	AATTGCTTGC	TGAGCTTTT	AACCTCTGTA	TGGTAATAT	AACTTCAGCC	TTTGAGAGTG	TAAAGAGGC	TATTAGTCAA	ACTTCCAAAT		
DR13 (parent)	*****	*G*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****G*
CV777	*****	*G*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****G*
Br1/87	*****	*G*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****G*
	3081	3100	3101		3120	3121	3140	3141	3160	3161	3180	3181	3190
DR13 (attenuated)	GTTTGAACAC	TGTGGCTCAT	GCGCTTACTA	AGGTCAAGA	GTTTGTAAAT	TCGCAGGGTT	CAGCTTTGAC	CCAACTTACC	ATACAGCTGC	AACAACAAT	CCAAGCCATT		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****A	*****G*	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****A	*****G*	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****A	*****G*	*****	*****	*****	*****
	3191	3210	3211		3230	3231	3250	3251	3270	3271	3290	3291	3300
DR13 (attenuated)	TCTAGTTCTA	TTGATGACAT	TTACTCCCGA	CTGGACATT	TTTCAGCCGA	TGTTCAAGTT	GATCGTCTCA	TCACCGGAG	ATTATCAGCA	CTTAATGCTT	TCGTTGCTCA		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3301	3320	3321		3340	3341	3360	3361	3380	3381	3400	3401	3410
DR13 (attenuated)	AACCTCACT	AAGTATACCT	AGGTTCAGGC	TAGCAGGAG	CTAGCACAGC	AAAAGTTAA	TGAGTGCCTC	AAATCGCAAT	CTCAGCGTTA	TGGTTTTTGT	GGTGGTATG		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3411	3430	3431		3450	3451	3470	3471	3490	3491	3510	3511	3520
DR13 (attenuated)	GCGAGCACAT	CTTCTCTCTG	GTACAGGCGG	CACCTCAGG	CCTGCTGTTT	TTACATACAG	TACTTGTACC	GGGTGATTTT	GTAATGTTA	TTGCATCGC	TGGCTATGC		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3521	3540	3541		3560	3561	3580	3581	3600	3601	3620	3621	3630
DR13 (attenuated)	GTTAATGGTG	ATATTGCGCT	GACTCTACGT	GAGCCTGGCT	TAGTCTTGT	TACGATGAA	CTTCAAACCT	ATACTGGGAC	GGAAATATTT	GTTTCATCGC	GACGTATGTT		
DR13 (parent)	*****	*A*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*A*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*A*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3631	3650	3651		3670	3671	3690	3691	3710	3711	3730	3731	3740
DR13 (attenuated)	TGAACTAGA	AAACCTACCG	TTAGTGATT	TGTTCAAAT	GAGAGTTGTG	TGGTCACTA	TGTCAATCTG	ACTAGGACC	AACTACCAGA	TGTAATCCCA	GATTACATCG		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3741	3760	3761		3780	3781	3800	3801	3820	3821	3840	3841	3850
DR13 (attenuated)	ATGTTAACAA	AAACACTTGAT	GAGATTCTAG	CTTCTGCGC	CAATAGAATT	GGTCTAGTC	TTCCCTAGA	TGTTTTAAT	GCCACTTATC	TTAATCTCAC	TGGTGAAT		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3851	3870	3871		3890	3891	3910	3911	3930	3931	3950	3951	3960
DR13 (attenuated)	GCAATTAG	AGCAGCGTTC	AGAGTCTCTC	AGTAATACTA	CAGAAGAGCT	CCGAAGCCTC	ATATATAATA	TCAACAACAC	ACTTGTGAC	CTTGAGTGGC	TCAACCGAGT		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	3961	3980	3981		4000	4001	4020	4021	4040	4041	4060	4061	4070
DR13 (attenuated)	TGAGACATAT	ATCAAGTGGC	CGTGGTGGGT	TGGTGAAT	ATTTTTATTG	TTCTCATCTT	TGTTGTGTCA	TTATTAGTGT	TCTGCTGCAT	TTCCACGGGT	TGTTGTGGAT		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	4071	4090	4091		4110	4111	4130	4131	4150	4151	4162		4255 4262
DR13 (attenuated)	GCTCGGGTGG	TTGCGGTGCC	TGTTTTTTCAG	GTTGTTGTAG	GGGTCTAGA	CTTCAACCTT	ACGAAGCTTT	TGAAAAGGTC	CACGTGCAGTGA	GAGCTCAA		
DR13 (parent)	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
CV777	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Br1/87	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
	4263	SR2	4278										
	TGTAGTCCAAATTAGA												

Fig. 2 continued

predicted to be N-glycosylated and a region of highly hydrophobic residues at positions 1,327–1,347, which is predicted to form an α -helix and to function as a membrane anchor. Similar to attenuated PEDV DR13, the Br1/87 S protein has 29 potential N-linked glycosylation sites and a hydrophobic stretch at positions 1,322–1,337 [10]. Although CV777 was a little different, it did contain 29 potential N-linked glycosylation sites [15]. Prediction of N-glycosylation sites using the ExPASy (Expert Protein Analysis System) Proteomics Server of the Swiss Institute of Bioinformatics (SIB) revealed that CV777 S protein contains 29 Asn-Xaa-Ser/Thr sequons and 22 asparagines that are predicted to be N-glycosylated. The Br1/87 and parent PEDV DR13 S proteins are a little different but still have 29

Asn-Xaa-Ser/Thr sequons and 22 asparagines that are predicted to be N-glycosylated. In the case of attenuated PEDV DR13, two (from N to K at 378, from T to I at 1,260) of the changes in the predicted amino acid sequence destroy N-linked glycosylation sites, while another change (from N to S at 114) creates a new glycosylation site when it compares to CV777 and Br1/87, respectively. There are two amino acid changes (from N to K at 378, from N to T at 1,193) destroying N-linked glycosylation sites and another change (from N to S at 114) creating a new glycosylation site when the attenuated PEDV DR13 is compared with parent PEDV DR13. Taken together, it appears that 2 nucleotide changes of 5 changes are thought to be simply strain differences because we reveal 1

(b)

DR13 (attenuated)	1	20	21	40	41	60	61	80	81	100	101	110
DR13 (parent)	MTPLIYFWLF	LPVLLTSLP	QDVTRCQSTI	NFRFRFSKFN	VQAPAVVVLG	GYLPSLWSSS	WYCGTGIETD	SGVHGIFLSY	IDSGQGFEIG	ISQEPDFDSG	YQLYLHKATN	
CV777	*RS*****L	*****P*****	*****T*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	
Br1/87	*RS*****L	*****P*****	*****T*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	
DR13 (attenuated)	111	130	131	150	151	170	171	190	191	210	211	220
DR13 (parent)	GNTSAIARLR	ICQFPNKT	GPTVNDVTTG	RNCLRNKATP	A-LQDGKNTV	VGITWDRV	TVFADKIYHF	YIKNWSRVA	TRCYNKRSCA	MQVYTPITY	MLNVTSGAGD	
CV777	*****N*****	*****S*****	*****S*****	*****YMR*****DI*****	*****L*****	*****L*****	*****L*****	*****L*****	*****R*****	*****R*****	*****R*****	
Br1/87	*****N*****	*****S*****	*****S*****	*****YMR*****DI*****	*****L*****	*****L*****	*****L*****	*****L*****	*****R*****	*****R*****	*****R*****	
DR13 (attenuated)	221	240	241	260	261	280	281	300	301	320	321	330
DR13 (parent)	GIYYEPTAN	CSGYAANVFA	TDSNGHIPEG	FSFNWFLLS	NDSLTLHGKV	VSNQPLLVC	LWAIPIKIYGL	GQFESFNQTM	DGVCNGAAAG	RAPELRFNI	NDTFVILAEG	
CV777	*****T*****	*****T*****	*****T*****	*****L*****	*****L*****	*****L*****	*****L*****	*****H*****	*****VD*****	*****VD*****	*****S*****	
Br1/87	*****T*****	*****T*****	*****T*****	*****L*****	*****L*****	*****L*****	*****L*****	*****H*****	*****VD*****	*****VD*****	*****S*****	
DR13 (attenuated)	331	350	351	370	371	390	391	410	411	430	431	440
DR13 (parent)	SILHHTALGT	NLSFVCSNSSL	DPHKAIFTIP	LGVTEVPYVC	FLKVDYKST	VYKFLAVLPP	TVKEIVITKY	GDVYVNGFVQ	DHLGLLDAVT	INFTGHGTD	DSVGFVIVAS	
CV777	*****V*****	*****L*****A*****	*****L*****A*****	*****A*****	*****N*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****I*****	
Br1/87	*****V*****	*****L*****A*****	*****L*****A*****	*****A*****	*****N*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****I*****	
DR13 (attenuated)	441	460	461	480	481	500	501	520	521	540	541	550
DR13 (parent)	TNFVDALIEV	QGTAIQRILY	CDDPVSQKLC	SQVAFDLDDG	FYPISSRNLL	SHEQIPISFVT	LPSFNDHSFV	MLTVSAAFVG	HSGANLIASD	TTINGFSSFC	VDTRQFTITL	
CV777	*****S*****	*****S*****	*****S*****	*****S*****	*****S*****	*****S*****	*****S*****	*****L*****S*****V*****	*****L*****S*****V*****	*****L*****S*****V*****	*****L*****S*****V*****	
Br1/87	*****S*****	*****S*****	*****S*****	*****S*****	*****S*****	*****S*****	*****S*****	*****L*****S*****V*****	*****L*****S*****V*****	*****L*****S*****V*****	*****L*****S*****V*****	
DR13 (attenuated)	551	570	571	590	591	610	611	630	631	650	651	660
DR13 (parent)	FYVINSYGY	VSKSQDSNCP	FTLQSVNDYL	SFSKFCVST	LLAGACTIDL	FGYPEGSGV	KFTSLYFQFT	KGESITGTPK	PLQGVTDVSF	MTLDVCKTYN	IYGFKGGELI	
CV777	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	
Br1/87	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	*****E*****	
DR13 (attenuated)	661	680	681	700	701	720	721	740	741	760	761	770
DR13 (parent)	TLTNSSEFLAG	VYVTSDSGQL	LAFKNVTSGA	VYSVTPCFPS	EQAAVYDDDI	VGVISLSSNS	TFNITRELPG	FFYHKDGSN	CTEPVLVYSN	IGVCKSGSITG	YVPLDQGVK	
CV777	*****I*****	*****I*****	*****I*****	*****N*****	*****N*****	*****N*****	*****N*****	*****N*****	*****N*****	*****N*****	*****P*****Y*****	
Br1/87	*****I*****	*****I*****	*****I*****	*****N*****	*****N*****	*****N*****	*****N*****	*****N*****	*****N*****	*****N*****	*****S*****Y*****	
DR13 (attenuated)	771	790	791	810	811	830	831	850	851	870	871	880
DR13 (parent)	IAPMVTGNIS	IPTNFSMSIR	TEYLQYNTPT	VSVDCVITYC	NGNSRCKQLL	TQYTAACKTI	ESALQLSARL	ESVEVNSMLT	ISEEALQLAT	ISSFNGDGYM	FTNVLVGSYV	
CV777	*****T*****	*****T*****	*****T*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	
Br1/87	*****T*****	*****T*****	*****T*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	*****A*****	
DR13 (attenuated)	881	900	901	920	921	940	941	960	961	980	981	990
DR13 (parent)	DPASGRVQK	GSFIEDLLFN	KVVTNGLTV	DEDYKRCSTG	RSVADLVCAQ	YYSGWVLPFG	VVDAEKLHMY	SASLIGGHAL	GGLTSAAALS	FSHAVQARLN	YLALQTDVLIQ	
CV777	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****I*****A*****P*****	*****I*****A*****P*****	*****I*****A*****P*****	*****I*****A*****P*****	
Br1/87	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****R*****V*****	*****I*****A*****P*****	*****I*****A*****P*****	*****I*****A*****P*****	*****I*****A*****P*****	
DR13 (attenuated)	991	1010	1011	1030	1031	1050	1051	1070	1071	1090	1091	1100
DR13 (parent)	RNQQLLAESF	NSAIGNLTSA	FESVKEAISQ	TSNGLNVAHF	ALTKVQEVVN	SQGSALTQLT	IQLQHNFOAI	SSSIDDIYSR	LDLISADVQV	DRLITGRLSA	LNAFVAQDTL	
CV777	*****K*****	*****K*****	*****K*****	*****K*****	*****N*****	*****N*****	*****V*****	*****V*****	*****L*****	*****L*****	*****L*****	
Br1/87	*****K*****	*****K*****	*****K*****	*****K*****	*****N*****	*****N*****	*****V*****	*****V*****	*****L*****	*****L*****	*****L*****	
DR13 (attenuated)	1101	1120	1121	1140	1141	1160	1161	1180	1181	1200	1201	1210
DR13 (parent)	KYTEVQASRK	LAQQKWNVCV	KSQSQRYGFC	GGDGHIFSL	VQAAQPGLLF	LHTVLPFGDF	VNVIADGLC	VNGDIALTLR	EPGLVLPFHE	LQTYTATFYE	VSSRRMPEFR	
CV777	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	
Br1/87	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	*****L*****A*****	
DR13 (attenuated)	1211	1230	1231	1250	1251	1270	1271	1290	1291	1310	1311	1320
DR13 (parent)	KPTVSDVFIQ	ESCVVTVNLT	TSDQLPDVIP	DYIDVNTLSD	EILASLPNRI	GPSLPLDVPN	ATYLNLTGEI	ADLEQRSSEL	SMTTEELRSL	IYNNITLVD	LEWLNREVEY	
CV777	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	
Br1/87	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	*****R*****	
DR13 (attenuated)	1321	1340	1341	1360	1361	1383						
DR13 (parent)	IKPFWWWLI	IFIVLIFVVS	LLVFCISTG	CCGCCGCCGA	CFSGCCRCGR	LQPYEAFKRVHQ						
CV777	*****V*****	*****V*****	*****V*****	*****V*****	*****V*****	*****V*****						
Br1/87	*****V*****	*****V*****	*****V*****	*****V*****	*****V*****	*****V*****						

Fig. 2 continued

nucleotide change (from A to C at 3,588) destroying N-linked glycosylation site through amino acid change (from N to T at 1,193) found in not other wild type PEDV but only parent PEDV DR13, and another change (from C to T, A in parent DR13 at 3,789) destroying N-linked glycosylation site through amino acid change (from T to I, N in parent DR13 at 1,260) found in both parent and attenuated PEDV DR13. Therefore, the fundamental cause of these differences

in N-linked glycosylation sites was 3 nucleotide changes and these are suggested to influence the pathogenicity of attenuated PEDV DR13.

Sequence homology analysis and phylogenetic analysis of S genes indicated that attenuated PEDV DR13 was highly homologous to CV777, Br1/87, JS-2004-2 and parent DR13, rather than to Spk1 and Chinju99 at the nucleotide and deduced amino acid sequence levels. In addition, attenuated PEDV DR13

Table 2 Nucleotide and deduced amino acid sequence homology of the S gene of attenuated PEDV DR13 and reference PEDVs

		Percentage similarity (%) ^a						
PEDV		CV777	Br1/87	JS-2004-2	Spk1	Chinju99	DR13 (parent)	DR13 (attenuated)
Percentage similarity (%) ^b	CV777	***	99.9	96.4	94.0	94.3	99.9	96.5
	Br1/87	99.7	***	96.3	94.0	94.3	99.8	96.4
	JS-2004-2	96.2	96.0	***	93.3	93.1	96.4	96.1
	Spk1	92.5	92.4	92.1	***	97.0	94.0	93.9
	Chinju99	92.8	92.8	91.6	95.0	***	94.3	93.5
	DR13 (parent)	99.7	99.4	96.2	92.4	92.6	***	96.6
	DR13 (attenuated)	95.7	95.4	95.6	92.0	91.6	95.7	***

^a Percentage of nucleotide similarity (upper triangle) are given
^b Percentage of deduced amino acid similarity (lower triangle) are given




Fig. 3 Phylogenetic trees generated on the basis of (a) nucleotide and (b) deduced amino acid sequences of the S gene region of attenuated PEDV DR13 and reference PEDVs. Trees constructed with neighbor-joining method using MEGA 3.1 program. Horizontal branch lengths are proportional to genetic distances between PEDV strains. Bootstrap figures are shown in

italics for the major nodes. The GenBank Accession Nos. of reference PEDVs for the S gene are AF353511 (CV777), AY653204 (JS-2004-2), AF500215 (Spk1), AY167585 (Chinju99), DQ862099 (parent DR13) and the EMBL Accession No. for Br1/87 is Z25483

was found to belong to a group that includes CV777, Br1/87, JS-2004-2 and parent DR13. More precisely, attenuated PEDV DR13 formed one subgroup with JS-2004-2. Taken together, it appears that attenuated PEDV DR13 is closely related to CV777, Br1/87, JS-2004-2 and parent DR13, rather than to Spk1 and Chinju99. It is notable that attenuated PEDV DR13 is especially close to the Chinese PEDV strain JS-2004-2 rather than to the Korean PEDV strains Spk1 and Chinju99, even though it is of Korean origin.

In the present study, the complete nucleotide and deduced amino acid sequences of the attenuated PEDV DR13 S gene were determined and compared to reference PEDVs, to find determinants of PEDV pathogenicity in the S gene. Phylogenetic trees were constructed and analyzed according to S gene nucleotide and deduced amino acid sequences. Similarities and differences among reference PEDVs, including attenuated PEDV DR13, were demonstrated, and these helped to elucidate the phylogenetic relationship of attenuated PEDV DR13 to other PEDVs. Moreover, the complete nucleotide and deduced amino acid sequences of the attenuated PEDV DR13 S gene will now form the basis for further functional exploration of both wild type and attenuated PEDV.

Acknowledgment This work was supported by the Research Project on the Production of Bio-organs (No. 200503010401) Ministry of Agriculture and Forestry, Republic of Korea.

References

1. P. Debouck, M. Pensaert, *Am. J. Vet. Res.* **41**, 219–223 (1980)
2. R. Ducatelle, W. Coussement, M. Pensaert, P. Debouck, J. Hoorens, *Arch. Virol.* **68**, 35–44 (1981)
3. M.B. Pensaert, P. de Bouck, *Arch. Virol.* **58**, 243–247 (1978)
4. P. Debouck, M. Pensaert, W. Coussement, *Vet. Microbiol.* **6**, 157–165 (1981)
5. M.B. Pensaert, in *Disease of Swine*, eds. by B.E. Straw, S. D’Allaire, W.L. Mengeling, D.I. Taylor (The Iowa University Press, Ames, IA, 1999), pp. 179–185
6. M.B. Pensaert, P. Debouck, D.J. Reynolds, *Arch. Virol.* **68**, 45–52 (1981)
7. L.S. Sturman, K.V. Holmes, *Adv. Virus Res.* **28**, 35–112 (1983)
8. S. Siddell, H. Wege, V. Ter Meulen, *J. Gen. Virol.* **64**, 761–776 (1983)
9. I. Correa, G. Jimenez, C. Sune, M.J. Bullido, L. Enjuanes, *Virus Res.* **10**, 77–93 (1988)
10. M. Duarte, H. Laude, *J. Gen. Virol.* **75**, 1195–1200 (1994)
11. S.H. Chang, J.L. Bae, T.J. Kang, J. Kim, G.H. Chung, C.W. Lim, H. Laude, M.S. Yang, Y.S. Jang, *Mol. Cells* **14**, 295–299 (2002)
12. S. Bernard, H. Laude, *J. Gen. Virol.* **76**, 2235–2241 (1995)

13. J.K. Fazakerley, S.E. Parker, F. Bloom, M.J. Buchmeier, *Virology* **187**, 178–188 (1992)
14. F.I. Wang, J.O. Fleming, M.C.L. Lai, *Virology* **186**, 742–749 (1992)
15. A. Bridgen, R. Kocherhans, K. Tobler, A. Carvajal, M. Ackermann, *Adv. Exp. Med. Biol.* **440**, 781–786 (1998)
16. D.S. Song, J.S. Yang, J.S. Oh, J.H. Han, B.K. Park, *Vaccine* **21**, 1833–1842 (2003)
17. F.A. Murphy, E.P.J. Gibbs, M.C. Horzinek, M.J. Studdert, *Veterinary Virology* (Academic Press, San Diego, USA, 1999)
18. H.F. Egberink, J. Ederveen, P. Callebaut, M.C. Horzinek, *J. Vet. Res.* **49**, 1320–1324 (1988)
19. M. Knuchel, M. Ackermann, H.K. Muller, U. Kihm, *Vet. Microbiol.* **32**, 117–134 (1992)
20. S.G. Yeo, M. Hernandez, P.J. Krell, E. Nagy, *Virus Gene* **26**(3), 239–246 (2003)
21. A. Bridgen, M. Duarte, K. Tobler, H. Laude, M. Ackermann, *J. Gen. Virol.* **74**(9), 1795–1804 (1993)
22. C.H. Kwon, B.J. Kwon, J.G. Lee, G.O. Kwon, Y.B. Kang, *Vaccine* **17**, 2546–2553 (1999)
23. S.Y. Kim, D.S. Song, B.K. Park, *J. Vet. Diagn. Invest.* **13**, 516–520 (2001)
24. M.M.C. Lai, *Annu. Rev. Microbiol.* **44**, 303–333 (1990)
25. C. Bernasconi, F. Guscelli, A. Utiger, K. Van Reeth, M. Ackermann, A. Pospischil, *Proc. Cong. Eur. Soc. Vet. Virol.* **3**, 542–546 (1994)